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Abstract 
Review on NCOA1, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
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Other names 





2p23.3 (Carapeti et al., 1998); Start: 24,492,050 bp; 
End: 24,770,702 bp; 278,652 bp; Orientation: Plus 
strand (GRCh38.p7) 
Local order 
From telomere to centromere: ITSN2, RPL36AP13, 
LOC105374329, NCOA1, RNA5SP88, RNU6-
936P, PTRHD1, LOC105369194, CENPO, ADCY3 
Local order of NCOA1. Local order is shown 
together with leading and subsequent genes on 
chromosome 2. The direction of arrows indicates 
transcriptional directions on the chromosome and 
arrow sizes approximate gene sizes. 
DNA/RNA 
NCOA1 is the firstly cloned nuclear hormone 
receptor co-activator (Onate et al., 1995; Xu et al., 
2009). The canonical transcript 
(ENST00000348332.7; NM_003743) includes 21 
exons, 19 of which are encoded (GRCh38.p10; 
http://www.ensembl.org). 
Numbers and illustrative sizes of exons of human NCOA1. Red boxes are the coding region and black boxes are 
the non-coding ones. 
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Transcription 
Four alternatively spliced isoforms of NCOA1 have 
firstly been illustrated (Kamei et al., 1996). 
Compared to NCOA1a, NCOA1b lacks the N-
termial domain, and NCOA1c, d and e have unique 
C-terminal sequences. NCOA1a and b have been 
shown to display diverse abilities to increase the 
estrogen receptor α ( ESR1 (Erα)) activity in cell 
lines (Kalkhoven et al., 1998; Xu et al., 2009). 
According to Ensembl database, there are eleven 
different transcripts of NCOA1 gene. Six of these 
transcripts encode two different proteins while five 
of them cannot encode protein. Lengths of the 
transcripts vary between 7405-501 bp 
(GRCh38.p10; http://www.ensembl.org). 
Protein 
NCOA1 gene encodes two similar proteins. The 
length of the canonical protein is 1441 amino acids 
with a molecular mass of 156,757 Da (UniPort ID: 
Q15788) and the length of the second protein is 1248 
amino acids with a molecular mass of 135,621 Da 
(UniProt ID: B5MCN7). Like the other SRCs 
(NCOA2 and NCOA3 (SRC-2 and 3)), NCOA1 
consists of three structural domains. The protein-
protein interaction is performed via an N-terminal 
basic helix-loop-helix-Per/ARNT/Sim (bHLH-PAS) 
domain. This domain is highly conserved amongst 
p160 SRC family and promotes interaction with the 
transcription factors, such as myogenin, MEF-2C 
and TEF. The central domain which consists of 
LXXLL motifs forming amphipathic alpha-helices 
supports interaction with nuclear hormone receptors. 
The C-terminal domain includes two transcription 
activation domains, AD1 and AD2. AD1 binds and 
recruits CREBBP and EP300 (CBP and p300 histone 
acetyltransferase (HAT)) for chromatin remodeling, 
which is critical for SRC-mediated transcriptional 
activation. AD2 interacts with histone 
methyltransferases, coactivator-associated arginine 
methyltransferase 1 (CARM1) and protein arginine 
methyltransferases (PRMT1). The C-terminus of 
NCOA1, like SRC-3, also includes a HAT activity 
domain (Torchia et al., 1997; Xu et al., 2009). 
Expression 
Chen et al. showed that NCOA1 was expressed in 
placental labyrinth (Chen et al., 2010). According to 
The Human Protein Atlas database, NCOA1 is 
highly expressed in cerebral cortex, hippocampus, 
cerebellum, thyroid gland, parathyroid gland, 
adrenal gland, lymph node, nasopharynx, bronchus, 
gallbladder, pancreas, oral mucosa, esophagus, 
stomach, duodenum, small intestine, colon, rectum, 
kidney, urinary bladder, testis, fallopian tube, breast, 
vagina and placenta. 
 
Expression profile of NCOA1 in human tissues. Data taken from The Human Protein Atlas 
(http://www.proteinatlas.org) in February, 2018. 
Localisation 
NCOA1 is synthesized in cytoplasm and imported 
into nucleus, and localized as speckles in both 
cytoplasm and nucleus. Localization to nucleus is 
performed thanks to nuclear localization signal 
located in between amino acids 18 and 36. After it  
 
 
display its function, it is exported to cytoplasm back, 
which is thought to inhibition of hormone action via 
NCOA1 degradation in cytoplasm. Exportation to 
cytoplasm back occurs owing to nuclear export 
signal located between amino acids 990 and 1038 
(Amazit et al., 2003). 
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Structure and functions of NCOA1 protein. When hormone (H) is bound to nuclear hormone receptors (NR), 
they recruit NCOA1 and interact with it via LXXLL motif in NCOA1. NCOA1 interacts with CBP, p300, 
KAT2B (p/ CAF), CARM1 and PRMT1 and recruits these coactivators to the chromatin for chromatin 
remodeling. Remodeling of chromatin enables binding of transcription factors and RNA polymerase II on the 
promoter region. NR interacts with NCOA1 via not only NRID domain but bHLH/PAS domain, which is also 
important for function of NCOA1. Data adapted from Xu et al., 2009.
 
Function 
NCOA1 increases the transcriptional activities of 
nuclear hormone receptors in a hormone-dependent 
manner. In addition to nuclear hormone receptors, 
NCOA1 and other SRCs are the coactivators of other 
transcription factors including NF-kB, Smads, E2F1, 
STATs, HIF1A, TP53, RB1, ETV4 (polyoma 
enhancer activator 3 (PEA3)) and ETS2. They 
support gene transcription by interacting with 
kinases, ubiquitin/sumoligases, phosphatases, 
histone acetyltransferases and histone 
methyltransferases (Qin et al., 2009; McBryan et al., 
2012; Xu et al., 2009). Due to its role in 
transcription, NCOA1 and other SRCs have a role in 
different physiological functions, including cell 
cycle and energy metabolism. NCOA1 itself is 
critical for organ physiology. It has been showed that 
NCOA1 deficiency strongly influenced mice 
reproductive organ development (Xu et al., 1998). 
NCOA1-/- mice also displayed partial resistance to 
sex steroids and thyroid hormone (Weiss et al., 1999; 
Kamiya et al., 2003). NCOA1 is also important for 
the gluconeogenesis. In liver, it is a coactivator of 
CEBPA (CEBPα) which regulates the pyruvate 
carboxylase gene, the limiting enzyme for 
gluconeogenesis, together with PPARG (PPARγ). 
Activated PPARγ recruits NCOA1 and other 
coregulators, such as PGC-1 and CBP/p300 in brown 
fat, and deficiency in NCOA1 results in drawbacks 
in activity of PGC-1. This drawback further 
decreases energy expenditure and causes obesity 
with high fat diet (Xu et al., 2009). 
Phosphorylation is critical in the functioning of SRC 
family proteins. Phosphorylation of SRCs alters their 
affinities for certain nuclear hormone receptors 
(Lopez et al., 2001; Rowan et al., 2000; Wu et al., 
2004; Giamas et al., 2009). Moreover, 
phosphorylation by different kinases via different 
Ser/Thr amino acids results in determination of 
down-stream processes. NCOA1 could be 
phosphorylated by EGF, IL6, CAMP, CCNA2 
(cyclin A2)/ CDK2, CDK1 and MAPK. Cyclin 
A2/Cdk2- and EGF-mediated phosphorylation 
increases progesterone receptor (PGR)-dependent 
transcription while IL-6-induced phosphorylation 
supports androgen receptor ( AR)-dependent 
transcription via ligand independency. Additionally, 
cAMP-mediated phosphorylation of NCOA1 
recruits p300 and CBP and activates PR-dependent 
transcription via ligand independency and MAPK-
induced NCOA1 phosphorylation enhances the 
affinity of NCOA1 towards AR in prostate cancer 
cells (Rowan et al., 2000; Wu et al., 2004; Giamas et 
al., 2009; Ueda et al., 2002; Rowan et al., 2000b; 
Gregory et al., 2004; Xu et al., 2009; Moore and 
Weigel, 2011). In addition to phosphorylation, 
sumoylation of NCOA1 at Lys731 and Lys774 by 
SUMO1 was showed to increase the interaction 
between PR and NCOA1, and upregulate PR-
mediated transcription (Chauchereau et al., 2003). 
In hormone-dependent progesterone receptor 
activity, NCOA1 was shown to be down-regulated in 
hormone-dependent manner like PR to activate the 
transcription of target genes. NCOA1 down-
regulation was illustrated to be predominantly in 
cytoplasmic compartment via proteasomal 
degradation and the down-regulation of NCOA1 
together with PR is critical for the regulation of 
transcription (Amazit et al., 2011). 
The interaction of NCOA1 with PR to regulate gene 
expression was partly underlined in a study where 
KAT7 (HBO1) (a member of the MYST acetylase 
family) was illustrated to modulate interaction of 
NCOA1 and PR in a hormone-dependent manner in 
human testis cell line, CV1 and human embryonic 
kidney cell line, HEK293 (Georgiakaki et al., 2006). 
NCOA1 has been shown to affect developmental 
processes. NCOA1 and NCOA3 double knockout 
mice died at early embryonic stage while single 
knockout mice lived normally, pointing a 
cooperative role of NCOA1 and NCOA2 in embryo 
survival. Moreover, morphologies of labyrinths of 
NCOA1 (together with NCOA3) knockout mice 
embryos were abnormal via altered expression of 
genes responsible for placental morphogenesis, and 
glucose metabolism (Chen et al., 2010). 
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Baldwin et al. showed that high-risk human 
papillomavirus type 16 (HPV16) E7 oncoprotein 
affected the localization and function of NCOA1; 
relocalized NCOA1 into cytoplasm and decreased 
NCOA1-mediated gene expression and NCOA1-
dependent histone acetyltransferase (HAT) activity 
in vivo and in vitro in cervical cancer cell line, HeLa 
(Baldwin et al., 2006). 
NCOA1 has also been linked to glucose metabolism. 
Under glucose deprivation, NCOA1 was proved to 
stabilize 26S proteasome and affect the expression of 
complex I of the mitochondrial electron transport 
chain (Motamed et al., 2014). 
Homology 
NCOA2 (SRC-2, TIF2 or GRIP1) and NCOA3 
(SRC-3, p/CIP, RAC3, AIB1, ACTR or TRAM-1) 
are homologous to NCOA1 and these three proteins 
are included in a family, called p160 SRC (Torchia 
et al., 1997; Xu et al., 2009). 
Mutations 
A single nucleotide polymorphism (SNP) in NCOA1 
(rs1804645; P1272S) was demonstrated to decrease 
ER activation while it increase protein life-time via 
blocking phosphorylation by glycogen synthase 3 
(GSK3B) in bone. Moreover, this SNP was linked to 
a decrease in hip and lumbar bone mineral density in 
women receiving tamoxifen (Hartmaier et al., 2011).  
 
Another SNP in NCOA1 (rs7948087) was associated 
to multiple myeloma phenotype in Chinese Han 
population (Peng et al., 2017).  
 
Four different SNPs in NCOA1 (rs11894248, 
rs17791703, rs7572475 and rs9309308) were linked 
to Kawasaki disease in Taiwanese people (Chen et 
al., 2014).  
 
Two chromosomal rearrangements affecting 
NCOA1 in patients with sarcoma subtypes were 
identified. In one study, a novel t(2;2)(q35;p23) 
translocation generating PAX3/NCOA1 fusion 
protein has been shown (Wachtel et al., 2004). 
Similar fusion protein was proved to be a result of 
inv(2)(q35p23) mutation (Huang et al., 2016).  
 
According to ClinVar database, huge chromosomal 
deletions and duplications in regions including 
NCOA1 gene have been submitted. These mutations 




NCOA1 has widely been studied particularly in 
breast and prostate cancer through its interaction 
status with estrogen receptor alpha, progesterone 
receptor and androgen receptor. 
Breast Cancer 
NCOA1 has been shown to be generally over-
expressed in breast cancer. Moreover, its over-
expression has been correlated with ERBB2 
expression, metastasis, cancer recurrence and poor 
disease-free survival (Wang et al., 2006; Fleming et 
al., 2004; Myers et al., 2004; Hudelist et al., 2003; 
McBryan et al., 2012; Qin et al., 2014; 2015). 
Furthermore, NCOA1 has also been demonstrated to 
be a predictor of breast cancer recurrence after 
therapy (Redmond et al., 2009). In a cohort study, 
NCOA1 was found to be over-expressed in 155 of 
312 breast cancer patients underwent radical 
resection, and NCOA1 expression was demonstrated 
to be correlated with Ki-67 and HER-2 expression. 
Moreover, NCOA1 and NANOG coexpression was 
showed to be significantly poorer postoperative 
disease-specific survival than those with no 
expression in the HER-2-positive group (Jin et al., 
2016). In a study, NCOA1 expression has also been 
correlated with a favorable response to tamoxifen in 
patients with recurrent breast cancer (Berns et al., 
1998). However, it has been showed that protein 
kinase A (PKA)-mediated of phosphorylation of 
estrogen receptor alpha at S305 caused alteration in 
orientation between ERα and NCOA1 leading to 
active transcription complex even in the presence of 
tamoxifen, resulting tamoxifen resistance in T47D 
and MCF7 breast cancer cell lines (Zwart et al., 
2007). Not only tamoxifen response, NCOA1 was 
shown to be involved in resistance to aromatase 
inhibitors in patient with breast cancer and breast 
cancer cell model. NCOA1 was proved to be over-
expressed in aromatase-resistant cells and patient 
tumors. NCOA1 was demonstrated to interact with 
transcription factor Ets2 and regulate transcription of 
MYC and MMP9 by which it affected tumor 
aggressiveness (McBryan et al., 2012). In breast 
adenocarcinoma cell line, MCF7, NCOA1 has been 
illustrated to have a role in ERα-mediated cell 
growth (Tai et al., 2000; Cavarretta et al., 2002). 
What is more, NCOA1 was shown to co-operate 
with MUC1, an ERα interactive protein (Wei et al., 
2006). NCOA1 has been also involved in cell 
proliferation and invasion via autocrine/paracrine 
activity of the SDF-1α- CXCL12 signaling pathway 
in MCF7 cell lines (Kishimoto et al., 2005). In 
another study, NCOA1 has been proved to support 
epithelial-mesenchymal transition (EMT), invasion, 
migration and metastasis of breast tumor cells via 
activating PEA3-mediated Twist (TWIST1) 
expression (Qin et al., 2009; Xu et al., 2009). In 
human ductal breast epithelial cell line, T47D, cyclin 
A2/Cdk2 was proved to phosphorylate NCOA1 and 
thus increase NCOA1/PR interaction and PR 
activity. Cyclin A2/Cdk2 as well as Cdk1 was 
further showed to phosphorylate seventeen sites in 
NCOA1 protein (Moore and Weigel, 2011). In vivo 
animal model studies have also proved the function 
of NCOA1 in breast tumorigenesis. Importantly, in 
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vivo NCOA1 knockdown was showed to cause 
reduction in expression of ERBB2, activation of Akt, 
inhibition of colony stimulating factor 1 ( CSF1) and 
prevention of macrophage recruitment to the tumor 
environment (Wang et al., 2009). Metastasis-focused 
study in mice figured out that NCOA1, together with 
FOS, up-regulated macrophage attractant CSF1 and 
increased macrophage recruitment, and metastasis 
(Qin et al., 2014). In a study conducted by Qin et al. 
NCOA1 was determined to up-regulate VEGFA by 
associating with FOS and HIF1α, potentiating 
angiogenesis in breast cancer mice models (Qin et 
al., 2015). Wang et al. proposed cardiac glycoside 
bufalin as an inhibitor of both SRC-3 and NCOA1, 
and showed that bufalin treatment decreased tumor 
growth in a mouse xenograft model of breast cancer 
(Wang et al., 2014). 
Prostate Cancer 
The expression profile of NCOA1 was not high in 
human tumors in general (Maki et al., 2006). Still, 
some studies proposed the expression of NCOA1 
was correlated with tumor grade (Agoulnik et al., 
2005; Gregory et al., 2001; Fujimoto et al., 2001). In 
one study, NCOA1 was shown to be more located to 
nucleus in androgen-independent prostate tumors 
(Maki et al., 2006). NCOA1 was demonstrated to 
increase AR-dependent cell proliferation in prostate 
cancer cell lines. Thus, NCOA1 knockdown was 
parallel to inhibition of proliferation in androgen-
dependent prostate cancer cell lines, LNCaP and C4-
2 while it did not affect the proliferation of AR-
negative prostate cancer cell lines, PC-3 and DU145 
(Agoulnik et al., 2005). This effect was further 
characterized by Luef et al. and proved that the effect 
was a result of upregulation of protein kinase D1 
(PRKD1) which was negatively regulated by AR. 
They also showed that the expression of NCOA1 
was high in patients with prostate cancer (Luef et al., 
2016).  Overall, NCOA1 supports prostate 
carcinogenesis in an androgen-dependent and -
independent manner (Xu et al., 2009). However, in 
vivo murine studies have showed that NCOA1 did 
not affect the prostate cancer tumorigenesis while 
other SRC family member, SRC-3 was critically 
affected (Tien et al., 2006). 
Endometrial Cancer 
NCOA1 phosporylation was demonstrated to 
significantly enhance agonistic activity of tamoxifen 
in endometrial cancer, pointing a possible function 
of NCOA1 in tamoxifen-induced proliferation and 
enhancement in risk of endometrial cancer via 
tamoxifen therapy (Shang and Brown, 2002; Shah 
and Rowan, 2005). 
Hepatoma 
NCOA1 together with PPARGC1A (PGC1α) was 
proved to be down-regulated in hepatoma cell line, 
HepG2 where it critically coactivates hepatocyte 
nuclear factor 4α (HNF4A) which is fundamental for 
liver development and hepatic gene expression. 
Overexpression of both NCOA1 and PCG1α 
increase the expression of HNF4α-regulated genes 
and triggered differentiation of HepG2 cells 
(Martinez-Himenez et al., 2006). Ma et al. showed 
thatMIR105-1 targeted NCOA1 in hepatocellular 
carcinoma. They checked the expression levels of 
miR-105-1 and demonstrated that it was down-
regulated in samples from patients with 
hepatocellular carcinoma compared to those of 
normal individuals. Moreover, down-regulation of 
miR-105-1 and up-regulation of NCOA1, as a result, 
were correlated with shorter overall survival (OS) 
and progression free survival (PFS) in hepatocellular 
carcinoma (Ma et al., 2017). 
Colon cancer 
In colorectal cancer-derived cell lines, DLD-1, HT29 
and HCT116, leptin and insulin signaling, via 
ERK1/2, were showed to increase MIR4443 
targeting and down-regulating both TRAF4 and 
NCOA1. Down-regulation of TRAF4 and NCOA1 
was illustrated to suppress invasion and proliferation 
of these cell lines (Meerson and Yehuda, 2016). 
Cervical cancer 
In cervical cancer cell line, HeLa overexpressing 
HPV16 E7, this epitope has been shown to relocalize 
NCOA1 into cytoplasm and decrease NCOA1-
dependent transcription via disrupting association 
with HAT (Baldwin et al., 2006). 
Myeloma 
In a cohort study with multiple myeloma patients in 
China, single nucleotide polymorphism in NCOA1 
gene (rs7948087) was shown to strongly associate 
with multiple myeloma phenotype, pointing NCOA1 
as a susceptibility gene for multiple myeloma 
patients in Chinese Han population (Peng et al., 
2017). 
Head and neck squamous cell 
carcinoma 
In a clinical study, Pavon et al. showed that 
expression of NCOA1 and creatine kinase 
mitochondrial 1(CKMT1) had prognostic 
significance in advanced-stage head and neck 
carcinoma (Pavon et al., 2015). 
Sarcoma 
Rhabdomyosarcoma is a soft sarcoma and is able to 
subclassified in to two groups: embryonal 
rhabdomyosarcoma ID: 5193> and alveolar 
rhabdomyosarcoma. In a microarray-based study, a 
novel translocation t(2;2)(q35;p23) causing a fusion 
PAX3/NCOA1 protein (Wachtel et al., 2004). In 
another study, in biphenotypic sinonasal sarcoma 
cases where t(2;4)(q36;q31)  PAX3/ MAML3 fusion 
has already been known, novel PAX3/NCOA1 
fusion has been demonstrated via inv(2)(q35p23). 
These cases were underlined to display desmin 
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reactivity and a small component of 
rhabdomyoblastic cells (Huang et al., 2016). 
Endometriosis 
Endometriosis (EMS; ectopic endometrium) is an 
estrogen-dependent and inflammatory complex 
disease where immunological factors and 
angiogenesis play a pivotal role in its pathogenesis 
(Gazvani and Templeton, 2006; Rizner 2009). Shi et 
al. showed that the expression of NCOA1 was 
greater in ectopic endometrium than that of normal 
endometrium, and NCOA1 was involved in the 
expression of stromal cell-derived factor 1 
(SCDF1/CXCL12) whose expression was induced 
by estradiol (Shi et al., 2014). 
Obesity 
NCOA1 together with p/CIP was demonstrated to 
control insulin signaling in vitro and in vivo. 
Knockout of these genes resulted in increase in 
glucose uptake and insulin sensitivity in both regular 
chow- and high fat diet-fed mice. Moreover, 
knockouts also brought about resistance to age-
related obesity and glucose intolerance through 
increase in the levels of insulin receptor substrate 1 
(IRS1; Wang et al., 2012). 
Inflammation 
Isoflavone biochanin A treatment of thymoma cell 
line, EL4 increased the levels ofIL7 which was 
linked to autoimmunity, chronic inflammation and 
protection against infections. This function of 
Biochanin A was proved to be a result of enhanced 
interaction between retinoic acid receptor-related 
orphan receptor RORC and NCOA1 via 
phosphorylation of signal transducer and activator of 
transcription 3 (STAT3; Takahashi et al., 2017). 
Kawasaki disease 
Kawasaki disease is a self-limited, acute and 
systemic vasculitis. Chen et al. showed that four 
SNPs (rs11894248, rs17791703, rs7572475 and 
rs9309308) in NCOA1 were associated with 
Kawasaki disease in 327 Taiwanese people (Chen et 
al., 2014). 
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